3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
2-pyrrolino-13-deoxyanthracycline derivatives, medical uses thereof, and a process for making them. A 2-pyrrolino-13-deoxyanthracycline and a 13-deoxyanthracycline can be administered to a patient simultaneously or sequentially in amounts to produce a synergistic therapeutic effect with increased potency and efficacy, compared to the sum of the effects of each drug when administered alone. A composition or preparation of a 2-pyrrolino-13-deoxyanthracycline and a 13-deoxyanthracycline for producing a potent anticancer therapeutic effect is also provided.
1. A compound represented by the formula:
wherein:
each R 1 , R 2 , and R 3 individually is H or OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is O or NH; and
R 6 is 2-pyrrolino-daunosamine or 2-pyrrolino-epidaunosamine; a pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixture thereof.
2. The compound of claim 1 , wherein said compound is a derivative of an anthracycline selected from the group consisting of 2-pyrrolino-13-deoxydoxorubicin, 2-pyrrolino-13-deoxydaunorubicin, 2-pyrrolino-13-deoxyepirubicin, 2-pyrrolino-13-deoxycarminomycin, and 2-pyrrolino-13-deoxyidarubicin and the 5-imino analogs thereof.
3. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier or excipient.
4. A pharmaceutical composition comprising the compound of claim 2 , and a pharmaceutically acceptable carrier or excipient.
5. A method for suppressing the growth of cells, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound comprising:
a 2-pyrrolino-13-deoxy anthracycline, or pharmaceutically acceptable salts thereof, said 2-pyrrolino-13-deoxy anthracycline having the formula:
wherein:
each R 1 , R 2 , and R 3 individually is H or OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is O or NH; and
R 6 is 2-pyrrolino-daunosamine or 2-pyrrolino-epidaunosamine;
pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixture thereof.
6. The method of claim 5 , wherein said compound is a derivative of an anthracycline selected from the group consisting of 2-pyrrolino-13-deoxydoxorubicin, 2-pyrrolino-13-deoxydaunorubicin, 2-pyrrolino-13-deoxyepirubicin, 2-pyrrolino-13-deoxycarminomycin, and 2-pyrrolino-13-deoxyidarubicin and the 5-imino analogs thereof.
7. A therapeutically effective amount of a synergistic combined preparation comprising a first compound and a second compound, wherein: the first compound is a 2-pyrrolino-13-deoxyanthracycline having the formula:
wherein:
each R 1 , R 2 , and R 3 individually is H or OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is O or NH; and
R 6 is 2-pyrrolino-daunosamine or 2-pyrrolino-epidaunosamine; pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixture thereof and
the second compound is a 13-deoxyanthracycline having the formula:
wherein
each of R 1 , R 2 and R 3 is independently selected from the group consisting of H and OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is selected from the group consisting of 0 and NH; and
R 6 is a sugar moiety; pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixture thereof and
wherein said therapeutically effective amount suppresses the growth of cells.
8. The synergistic combined preparation of claim 7 , wherein said first compound is a derivative of an anthracycline selected from the group consisting of 2-pyrrolino-13-deoxydoxorubicin, 2-pyrrolino-13-deoxydaunorubicin, 2-pyrrolino-13-deoxyepirubicin, 2-pyrrolino-13-deoxycarminomycin, and 2-pyrrolino-13-deoxyidarubicin; pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixtures thereof and the 5-imino analogs thereof and said second compound is a derivative of an anthracycline selected from the group consisting of 13-deoxydoxorubicin, 13-deoxydaunorubicin, 13-deoxyepirubicin, 13-deoxycarminomycin, 13-deoxyidarubicin, 13-deoxyannamycin, and 13-deoxyamrubicin and the 5-imino analogs thereof; pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixtures thereof.
9. A pharmaceutical composition comprising the synergistic combined preparation of claim 7 , and a pharmaceutically acceptable carrier or excipient.
10. A pharmaceutical composition comprising the synergistic combined preparation of claim 8 , and a pharmaceutically acceptable carrier or excipient.
11. The synergistic combined preparation of claim 7 wherein said second compound is present in an amount that is lower than its therapeutically effective amount.
12. The synergistic combined preparation of claim 11 wherein the weight ratio of the second compound to the first component is about 0.005 to about 0.10:1.
13. The synergistic combined preparation of claim 7 wherein said first compound is present in an amount that is lower than its therapeutically effective amount.
14. The synergistic combined preparation of claim 13 wherein the weight ratio of the first compound to the second component is about 0.005 to about 0.10:1.
15. A method for suppressing the growth of cells with a synergistic combined preparation of a first compound and a second compound, comprising administering to a mammal in need thereof a therapeutically effective amount of said synergistic combined preparation, said first compound being a 2-pyrrolino-13-deoxyanthracycline having the formula:
wherein:
each R 1 , R 2 , and R 3 individually is H or OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is O or NH; and
R 6 is 2-pyrrolino-daunosamine or 2-pyrrolino-epidaunosamine; pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixture thereof, and
said second compound being a 13-deoxyanthracycline having the formula:
wherein
each of R 1 , R 2 and R 3 is independently selected from the group consisting of H and OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is selected from the group consisting of O and NH; and
R 6 is a sugar moiety; pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixture thereof and
wherein said therapeutically effective amount suppresses the growth of cells.
16. The method of claim 15 , wherein said first compound is a derivative of an anthracycline selected from the group consisting of 2-pyrrolino-13-deoxydoxorubicin, 2-pyrrolino-13-deoxydaunorubicin, 2-pyrrolino-13-deoxyepirubicin, 2-pyrrolino-13-deoxycarminomycin, and 2-pyrrolino-13-deoxyidarubicin and the 5-imino analogs thereof; pharmaceutically acceptable salts thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixtures thereof and the second compound is a derivative of an anthracycline selected from the group consisting of 13-deoxydoxorubicin, 13-deoxydaunorubicin, 13-deoxyepirubicin, 13-deoxycarminomycin, 13-deoxyidarubicin, 13-deoxyannamycin, and 13-deoxyamrubicin and the 5-imino analogs thereof; pharmaceutically acceptable salt thereof, deuterated form thereof, isomer thereof, solvate thereof, and mixtures thereof.
17. The method of claim 15 wherein said second compound is administered in an amount that is lower than its therapeutically effective amount.
18. The method of claim 17 wherein the weight ratio of the second compound to the first component is about 0.005 to about 0.10:1.
19. The method of claim 15 wherein said second compound is administered in an amount that is lower than its therapeutically effective amount.
20. The method of claim 19 wherein the weight ratio of the first compound to the second component is about 0.005 to about 0.10:1.